Charter Oak Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Charter Oak Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17	Closed	-$3K	–	796
2022 Q2	$3K	Hold	17	–	–	﹤0.01%	801
2022 Q1	$2K	Hold	17	–	–	﹤0.01%	898
2021 Q4	$3K	Hold	17	–	–	﹤0.01%	757
2021 Q3	$5K	Hold	17	–	–	﹤0.01%	680
2021 Q2	$7K	Hold	17	–	–	﹤0.01%	625
2021 Q1	$9K	Hold	17	–	–	﹤0.01%	563
2020 Q4	$6K	Buy	+17	New	+$6.76K	﹤0.01%	579

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Charter Oak Capital Management's TCRT Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 17 shares — an estimated $3K sold.

Charter Oak Capital Management first reported a position in TCRT in Q4 2020 and held it in 7 quarters. The position peaked at $9K in Q1 2021. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

Charter Oak Capital Management reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 17 Alaunos Therapeutics shares in Q3 2022, an estimated $3K.
Charter Oak Capital Management first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's Alaunos Therapeutics position peaked at $9K in Q1 2021.
125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.